CanaF Targets Multiple Oncology INDs and Explores Global Licensing for AMD Therapy

According to a recent LinkedIn post from BioSpectator Inc, portfolio company CanaF is reportedly targeting the submission of three additional oncology investigational new drug applications, including bispecific antibody drug conjugate candidates, by 2027. The post indicates that CanaF does not limit itself to specific therapeutic modalities and has been entering partnerships with domestic pharmaceutical companies almost annually since 2022.

The LinkedIn post notes that these licensing deals are beginning to progress into clinical development stages and that CanaF has received a total of KRW 15.9 billion in upfront payments to date. The post also suggests that CanaF is evolving its partnership structure toward 50:50 arrangements to retain more rights, with oncology candidates under this strategy expected to enter clinical trials sequentially starting next year.

In addition, the post highlights that CanaF is pursuing global partnerships, citing its age-related macular degeneration therapy candidate KNP-301, a C3bxVEGF bispecific antibody. According to the post, this asset is currently the subject of global out-licensing discussions with an undisclosed U.S. company that is described as a leading player in ophthalmology.

For investors, the described cadence of IND filings, the scale of upfront payments, and the shift toward more balanced deal structures may point to a business model increasingly geared toward value capture from partnered assets. If the referenced global out-licensing discussions for KNP-301 advance to formal agreements, this could enhance CanaF’s and, by extension, BioSpectator Inc’s visibility in both oncology and ophthalmology-focused biotech markets.